

## Supplementary Information – Online Resource 13

Evaluating cost-utility of continuous glucose monitoring in individuals with type 1 diabetes: a systematic review of methods and quality of studies using decision models and/or empirical data.

de Jong LA<sup>1\*</sup> (ORCID ID: 0000-0001-8814-0670), Li X<sup>2</sup> (ORCID ID: 0000-0002-0225-6937), Emamipour S<sup>3</sup>, van der Werf S<sup>4</sup> (ORCID ID: 0000-0001-5856-7657), Postma MJ<sup>1,5</sup>, van Dijk PR<sup>6</sup> (ORCID ID: 0000-0002-9702-6551), Feenstra TL<sup>2</sup> (ORCID ID: 0000-0002-5788-0454)

<sup>1</sup> Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

<sup>2</sup> Unit of Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands

<sup>3</sup> Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

<sup>4</sup> Central Medical Library, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

<sup>5</sup> Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands

<sup>6</sup> Department of Endocrinology. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

\*Corresponding author: [t.l.feenstra@rug.nl](mailto:t.l.feenstra@rug.nl)

**Table 1. Overview of scores for Philips checklist per item, studies 1-16 (CORE model studies)**

	Roze (2015) [1]	Roze (2016) [2]	Roze (2016) [3]	Roze (2017) [4]	Roze (2019) [5]	Roze (2019) [6]	Roze (2020) [7]	Roze (2021) [8]	Roze (2021) [9]	Roze (2021) [10]	Jendle (2017) [11]	Jendle (2019) [12]	Jendle (2021) [13]	Kamble (2012) [14]	Gomez (2016) [15]	Riemsma (2016) [16]
1	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
2	YES	NA	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
3	NO	NO	NO	NO	NO	NO	YES	NO	YES	NO	NO	NO	NO	NO	NO	YES
4	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
5	NO	YES	YES	NO	YES	YES	YES	YES	YES	YES	NO	NO	YES	YES	YES	YES
6	YES	YES	YES	YES	Y/N	Y/N	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
7	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
8	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
9	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
10	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	NR
11	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
12	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
13	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
14	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	YES	YES	YES	YES
15	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
16	NO	NO	NO	NO	NO	NO	Y/N	NO	NO	NO	NO	NO	NO	NO	NO	YES
17	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NA
18	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
19	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
20	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
21	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
22	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
23	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
24	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	YES
25	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	YES
26	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	YES	YES	YES	YES
27	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	YES
28	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
29	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NR	NR	NR	YES
30	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
31	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES
32	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	YES	YES	YES	YES

33	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	NR
34	YES	YES	YES	YES	YES	YES	NA	NA	NA	NA	YES	NA	NR	NR	NR	YES	
35	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	YES	
36	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	YES	
37	NO	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
38	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
39	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	
40	YES	YES	NO	YES	YES	YES	NO	YES	NO	YES	NO	NO	YES	YES	YES	YES	
41	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	YES	
42	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	YES	YES	YES	YES	
43	NO	NA	NA	NA	NA	NA	NO	NO	NA	NA	NA	NA	NR	NR	YES	YES	
44	YES	NA	NA	NA	NO	NA	YES	YES	NA	NA	NA	NA	NA	NA	NA	YES	
45	YES	NO	YES	NO	NO	NO	NO	NO	YES	NO	NO	YES	NO	NO	NO	YES	
46	NA	NO	NA	NO	NO	NO	NO	NO	NA	NO	NO	NA	NO	NO	NO	NA	
47	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	NO	NO	NO	YES	
48	YES	NO	YES	NO	NO	NO	NO	NO	YES	NO	NO	YES	YES	YES	NO	YES	
49	YES	YES	YES	YES	YES	YES	YES	NO	YES	NO	YES	YES	YES	YES	NO	YES	
50	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
51	YES	NO	NO	NO	NO	NO	YES	YES	NO	NO	NO	NO	NO	NO	YES	YES	
52	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
53	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NR	NR	NR	NR	
54	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	
55	NA	NA	NO	NO	NO	NO	NA	NA	NA	NA	NA	NA	NA	YES	YES	YES	
56	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	NR	NR	NR	NR	
57	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES	YES	YES	

Abbreviations: NA, not applicable; NR, not reported; Y/N, yes/no.



32	YES	YES	NR	NR	NR	NR	NR	NR	YES	NR	YES	NR	NR	YES	NR	NR
33	NR	NR	NA	NA	NA	NA	NA	NA	NA	NO	NR	NR	NA	NR	NR	NO
34	NR	YES	NO	YES	NO	YES	NR	NO	NA	NA	YES	NA	NA	NR	YES	YES
35	NR	NR	NR	NO	NO	NO	NO	NO	YES	NO	YES	YES	YES	YES	NO	NO
36	NR	NR	NR	NR	NO	NR	NR	NR	YES	NO	YES	NA	NA	YES	NO	NO
37	YES	YES	YES	YES	YES	YES	YES	NO	YES	YES/NO	YES	YES	YES	YES	YES	YES
38	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
39	NR	NR	NR	NR	NR	YES	NR	NR	NR	NR	NR	NA	NA	NR	YES	NR
40	YES	YES	NO	YES	YES	YES	NO	NO	YES	YES	YES	YES	YES	YES	YES	YES
41	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	YES	NA	NA	NR	NA	NR
42	YES	YES	NO	NO	YES	NO	NO	NO	NO	NO	YES	YES/NO	NO	YES	YES	NO
43	YES	NR	NO	NO	NO	NA	NA	NA	YES	YES	YES	YES	YES	NR	YES	NA
44	NA	NA	YES	NO	NO	NA	NA	NA	YES	YES	YES	YES	YES	NA	YES	NA
45	YES	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
46	NA	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO	NO
47	YES	YES	YES	YES	YES	YES	YES	NO	NO	NO	YES	YES	YES	NO	YES	YES
48	YES	YES	NO	NO	NO	NO	NO	NO	NO	NO	YES	YES/NO	YES/NO	YES	NO	NO
49	YES	NO	NO	NO	NO	NO	NO	NO	YES	NO	NO	YES/NO	YES/NO	YES	YES	NO
50	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES	YES
51	YES	NO	YES	YES	YES	NO	NO	NO	YES	YES	YES	YES	YES	NO	YES	NO
52	YES	YES	NO	NO	NO	NO	NO	NA	YES	YES	YES	YES	YES	YES	YES	YES
53	NR	NR	YES	YES	YES	YES	YES	YES	YES	NO	NO	NO	NO	NR	NR	NO
54	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES	YES	YES	YES	YES	YES	YES
55	YES	NA	YES	NO	YES	NA	NA	NA	NO	YES	NA	NA	NA	NA	NA	NA
56	NR	NR	YES	YES	YES	YES	YES	YES	NA	NO	NA	NA	NA	NR	NO	NO
57	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES	YES	NO	YES	NO	NO	YES

Abbreviations: NA, not applicable; NR, not reported; Y/N, yes/no.

**Table 3. Total quality scores per item**

Item no	YES	NO	Y/N	NR	NA	QUALITY SCORE
1	23	9	0	0	0	71.9
2	23	0	0	0	9	100.0
3	6	26	0	0	0	18.8
4	32	0	0	0	0	100.0
5	24	8	0	0	0	75.0
6	29	1	2	0	0	93.8
7	32	0	0	0	0	100.0
8	30	2	0	0	0	93.8
9	31	0	0	1	0	96.9
10	2	0	0	30	0	6.3
11	29	2	1	0	0	92.2
12	27	3	2	0	0	87.5
13	29	1	2	0	0	93.8
14	3	5	24	0	0	46.9
15	30	2	0	0	0	93.8
16	6	20	6	0	0	28.1
17	2	24	0	0	6	7.7
18	32	0	0	0	0	100.0
19	30	1	1	0	0	95.3
20	3	29	0	0	0	9.4
21	31	1	0	0	0	96.9
22	28	4	0	0	0	87.5
23	31	1	0	0	0	96.9
24	4	24	4	0	0	18.8
25	6	0	0	26	0	18.8
26	5	0	3	24	0	20.3
27	3	28	1	0	0	10.9
28	0	0	1	31	0	1.6
29	3	6	0	0	23	33.3
30	5	0	0	27	0	15.6
31	29	3	0	0	0	90.6
32	2	0	0	30	0	6.3
33	0	0	0	32	0	0.0
34	14	0	0	1	17	93.3
35	6	26	0	0	0	18.8
36	4	26	2	0	0	15.6
37	29	1	1	1	0	92.2
38	30	0	1	1	0	95.3
39	5	27	0	0	0	15.6
40	24	8	0	0	0	75.0
41	2	0	0	30	0	6.3

<b>42</b>	4	27	1	0	0	<b>14.1</b>
<b>43</b>	9	10	0	0	13	<b>47.4</b>
<b>44</b>	11	3	0	0	18	<b>78.6</b>
<b>45</b>	2	24	6	0	0	<b>15.6</b>
<b>46</b>	0	24	0	0	8	<b>0.0</b>
<b>47</b>	24	7	1	0	0	<b>76.6</b>
<b>48</b>	10	19	3	0	0	<b>35.9</b>
<b>49</b>	17	13	2	0	0	<b>56.3</b>
<b>50</b>	32	0	0	0	0	<b>100.0</b>
<b>51</b>	14	17	1	0	0	<b>45.3</b>
<b>52</b>	31	0	0	0	1	<b>100.0</b>
<b>53</b>	1	31	0	0	0	<b>3.1</b>
<b>54</b>	31	1	0	0	0	<b>96.9</b>
<b>55</b>	8	6	0	0	18	<b>57.1</b>
<b>56</b>	24	0	0	0	8	<b>100.0</b>
<b>57</b>	26	6	0	0	0	<b>81.3</b>

Abbreviations: NA, not applicable; NR, not reported; Y/N, yes/no.

**Table 4. Total quality scores per study.**

	Yes	Y/N	NO	NR	NA	
<b>1</b>	29	4	14	8	2	<b>56.36</b>
<b>2</b>	27	1	16	8	5	<b>52.88</b>
<b>3</b>	28	3	14	8	4	<b>55.66</b>
<b>4</b>	28	1	17	8	3	<b>52.78</b>
<b>5</b>	28	2	17	8	2	<b>52.73</b>
<b>6</b>	28	2	16	8	3	<b>53.70</b>
<b>7</b>	23	2	19	9	4	<b>45.28</b>
<b>8</b>	29	1	16	8	3	<b>54.63</b>
<b>9</b>	29	2	12	8	6	<b>58.82</b>
<b>10</b>	27	1	16	8	5	<b>52.88</b>
<b>11</b>	27	1	17	8	4	<b>51.89</b>
<b>12</b>	27	2	14	8	6	<b>54.90</b>
<b>13</b>	27	1	17	8	4	<b>51.89</b>
<b>14</b>	29	2	15	8	3	<b>55.56</b>
<b>15</b>	28	1	17	8	3	<b>52.78</b>
<b>16</b>	47	2	2	4	2	<b>87.27</b>
<b>17</b>	33	1	11	8	4	<b>63.21</b>
<b>18</b>	26	2	17	8	4	<b>50.94</b>
<b>19</b>	27	1	19	8	2	<b>50.00</b>
<b>20</b>	28	1	19	8	1	<b>50.89</b>
<b>21</b>	30	1	16	7	3	<b>56.48</b>
<b>22</b>	28	1	14	8	6	<b>55.88</b>
<b>23</b>	23	1	19	9	5	<b>45.19</b>
<b>24</b>	19	1	20	10	7	<b>39.00</b>
<b>25</b>	39	0	11	3	4	<b>73.58</b>
<b>26</b>	25	2	21	7	2	<b>47.27</b>
<b>27</b>	45	0	7	3	2	<b>81.82</b>
<b>28</b>	25	10	9	7	6	<b>58.82</b>
<b>29</b>	31	12	4	5	5	<b>71.15</b>
<b>30</b>	29	2	15	7	4	<b>56.60</b>
<b>31</b>	37	1	11	5	3	<b>69.44</b>
<b>32</b>	22	1	24	6	4	<b>42.45</b>

Abbreviations: NA, not applicable; NR, not reported; Y/N, yes/no.



Model quality: Philips, scores per paper




Figure 1. Total quality scores per study.

## References

1. Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. *Diabet Med.* 2015;32:618–26.
2. Roze S, Smith-Palmer J, Valentine W, Payet V, De Portu S, Papo N, et al. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. *Diabetes Technol Ther.* 2016;18:75–84.
3. Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, De Portu S, et al. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. *J Med Econ.* 2016;19:236–42.
4. Roze S, de Portu S, Smith-Palmer J, Delbaere A, Valentine W, Ridderstråle M. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. *Diabetes Res Clin Pract.* 2017;128:6–14.
5. Roze S, Smith-Palmer J, De Portu S, Delbaere A, De Brouwer B, De Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. *Clinicoecon Outcomes Res.* 2019;11:73–82.
6. Roze S, Smith-Palmer J, De Portu S, Özdemir Saltik AZ, Akgül T, Deyneli O. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. *Diabetes Technol Ther.* 2019;21:727–35.
7. Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. *Diabetes Care.* 2020;43:2411–7.
8. Roze S, Isitt JJ, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. *Clinicoecon Outcomes Res.* 2021;13:717–25.
9. Roze S, Buompiensiere MI, Ozdemir Z, de Portu S, Cohen O. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. *J Med Econ.* 2021;24:883–90.
10. Roze S, Isitt JJ, Smith-Palmer J, Lynch P, Klinkenbijn B, Zammit G, et al. Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. *Diabetes Ther.* 2021;12:235–46.
11. Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, et al. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. *Diabetes Ther.* 2017;8:1015–30.
12. Jendle J, Pöhlmann J, De Portu S, Smith-Palmer J, Roze S. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. *Diabetes Technol Ther.* 2019;21:110–8.
13. Jendle J, Buompiensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. *Diabetes Ther.* 2021;12:2977–91.
14. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. *Value Health.* 2012;15:632–8.
15. Gomez AM, Alfonso-Cristancho R, Orozco JJ, Lynch PM, Prieto D, Saunders R, et al. Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. *Endocrinol Nutr.* 2016;63:466–74.

16. Riemsma R, Ramos IC, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, et al. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. *Health Technol Assess*. 2016;20:1–252.
17. Chaugule S, Graham C. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. *J Med Econ*. 2017;20:1128–35.
18. Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden. *Eur Endocrinol*. 2018;14:73–9.
19. Conget I, Martín-Vaquero P, Roze S, Elías I, Pineda C, Álvarez M, et al. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. *Endocrinol Diabetes Nutr*. 2018;65:380–6.
20. Nicolucci A, Rossi MC, D’Ostilio D, Delbaere A, de Portu S, Roze S. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. *Nutr Metab Cardiovasc Dis*. 2018;28:707–15.
21. Zhao X, Ming J, Qu S, Li HJ, Wu J, Ji L, et al. Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China. *Diabetes Ther*. 2021;12:3079–92.
22. Isitt JJ, Roze S. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia: Response to letter from Hellmund, Richard and Welsh, Zoe. *Diabet Med*. 2023;40.
23. Lambadiari V, Ozdemir Saltik AZ, De Portu S, Buompiensiere MI, Kountouri A, Korakas E, et al. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. *Diabetes Technol Ther*. 2022;24:316–23.
24. Serné EH, Roze S, Buompiensiere MI, Valentine WJ, De Portu S, de Valk HW. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands. *Adv Ther*. 2022;39:1844–56.
25. Wan W, Skandari MR, Minc A, Nathan AG, Winn A, Zarei P, et al. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. *Diabetes Care*. 2018;41:1227–34.
26. McQueen RB, Ellis SL, Campbell JD, Nair K V., Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. *Cost Eff Resour Alloc*. 2011;9.
27. Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2018 Feb 21;18(2):1-160. eCollection 2018.
28. Pease A, Zomer E, Liew D, Earnest A, Soldatos G, Ademi Z, et al. Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. *Diabetes Technol Ther*. 2020;22:812–21.
29. Pease A, Callander E, Zomer E, Abraham MB, Davis EA, Jones TW, et al. The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. *Diabetes Care*. 2022;45:1971–80.
30. Huang ES, O’Grady M, Basu A, Winn A, John P, Lee J, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. *Diabetes Care*. 2010;33:1269–74.
31. García-Lorenzo B, Rivero-Santana A, Vallejo-Torres L, Castilla-Rodríguez I, García-Pérez S, García-Pérez L, et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. *J Eval Clin Pract*. 2018;24:772–81.
32. Rotondi MA, Wong O, Riddell M, Perkins B. Population-Level Impact and Cost-effectiveness of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring Technologies for Adults With Type 1 Diabetes in Canada: A Modeling Study. *Diabetes Care*. 2022;45:2012–9.